There were 176 press releases posted in the last 24 hours and 452,977 in the last 365 days.

Oscor launches Breezeway II Transseptal Access Delivery System

PALM HARBOR, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- Oscor receives CE Mark, FDA, and Health Canada clearance on its Breezeway II next generation transseptal access delivery system. Available in inner diameter sheath sizes ranging from 6F to 14F and with various length and curve configurations. The Breezeway II delivery system features a fully integrated valve bypass and device loader system. The Breezeway II delivery system is designed to allow streamlined and controlled delivery of complex devices via transseptal access to the left side of the heart, while providing complete hemostasis. Ideally suited for minimal invasive electrophysiology and structural heart applications, the Breezeway II integrated delivery system is available immediately under Oscor and OEM branding.

About Oscor
Oscor Inc, headquartered in Palm Harbor, Florida USA, is a leading manufacturer and OEM provider of turnkey vascular introducer, delivery, guiding sheath systems and implantable leads.  Oscor focuses on making products that improve patient’s health and quality of life. The company specializes in identifying and refining minimally invasive solutions that streamline challenging procedures for the benefit of our patients and clinicians.

 

Contact
sales@oscor.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c0d9d4e5-4ee3-4820-a7ae-cf70c4ea3bf6


Oscor Launches Breezeway II Delivery System

Oscor Launches Breezeway II Transseptal Access Delivery System with Loader

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.